Transaction overview
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC disclosed the sale of common stock in Sionna Therapeutics, Inc. (NASDAQ:SION) totaling $2,472,342. The dispositions took place on April 17 and April 18, 2026, under a pre-arranged trading arrangement governed by a 10b5-1 plan.
The sellers executed 55,345 shares in total. On April 17, 52,397 shares were sold at $44.68 per share. A further 2,948 shares were sold on April 18 at $44.52 per share. The transaction prices therefore ranged from $44.52 to $44.68.
Ownership and control structure
After these sales, OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC together hold 2,964,774 shares of Sionna Therapeutics common stock. Those securities are held of record by OrbiMed Private Investments VIII, LP - referred to as OPI VIII. OrbiMed Capital GP VIII LLC is the general partner of OPI VIII, and OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VIII LLC.
Because of those relationships, OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC may be considered to have voting and investment power over the shares held by OPI VIII. Members of the management committee of OrbiMed Advisors LLC - Carl L. Gordon, Sven H. Borho, and W. Carter Neild - disclaim beneficial ownership of the shares held by OPI VIII. Separately, Peter A. Thompson, a member of OrbiMed Advisors LLC, holds a seat on Sionna Therapeutics' board of directors.
Market context and analyst activity
The timing of these sales coincides with significant market moves for Sionna. According to InvestingPro data, the company's stock has risen approximately 250% over the past year. Despite the recent trades occurring in the $44.52 to $44.68 range, the share price at the time of reporting stands at $41.79, which is below the sale prices. InvestingPro's Fair Value analysis identifies the stock as appearing overvalued.
Analyst coverage has also been active. Guggenheim raised its price target on Sionna Therapeutics to $50 while maintaining a Buy rating. Citizens initiated coverage with a Market Outperform rating and set a $63 price target; Citizens analyst Jonathan Wolleben used a risk-adjusted, discounted cash flow model in arriving at that target.
From a company disclosure perspective, Sionna reported $310.3 million in cash at the end of fiscal 2025 and projected its cash runway extending to 2028. The company is also advancing clinical development with a Phase IIa study named preciSION, which seeks a minimum improvement of 10 mmol/L in sweat chloride (SwCl) for F508del homozygous cystic fibrosis patients.
Takeaway
The OrbiMed sales were executed through a planned trading program and reduced the firms' holdings by 55,345 shares while leaving a substantial residual position. These trades occurred against a backdrop of strong historical stock performance and varied analyst views on Sionna's prospects and valuation. The company's reported cash position and ongoing clinical program were noted alongside recent analyst price targets.